参苓白术散加减联合阿帕替尼治疗晚期胃癌的临床效果

-26.

Journal

ofClinical

Medicine

inPractice

43

210022)

60

2

33

2

(P<0.05)

R735.2

R22

A

1672-2333(2222)22-023-04

D0I

10.7619/jcmp.

222222007

Clinical

effect

of

modified

Shenling

Baizhu

Powder

combined

with

apatinib

in

treeting

advanced

gastria

cancer

LIYu,

LINGBofan,XUE0£

DAIHong

(Departmentof'Oncology,JiangsuProvincialHospitalof'TraditionalChinese

Medicine,Naging,Jiangsu,210029)

Abstraci

:Objechvv

ToobservethdclinicaiefficacyofmoUifiedShedlingBaizhrPowdercom-

biaedwithaaatinininthetredtmeriofaivaaced

gasthccaacer.

Methods

Atotaiof66patieris

were

raniomiy

divinedintotoognupt,

with35casdtineactgnup.Thetreatmedignupwattreatedwith

moUifiedSdedlinaBaizhrPowOdncombined

withaaatinin,whilethdceutrotgnop

watonlytreated

withaaatinin.Thetreatmedieffectanithdiacinedco

ofddant

reactioot

werecomparedbetheed

thd

twogroopt.

Resultt

Thediseasecootroorateandeffectiverateoftraaitiooai

Chinesemedicine

syn­

dromeofthetreatwedt

groopweresivnificanWyhighea,

theiacinedco

ofaaversereactiooatovagrat-

ooewassivnificantinloweathaathatofthe

coo

WoIgroop(P<2.23).Conclusion

Theclinicai

effectofmooifiedShedlineBaizhpPowdeacombiaedwithaaatinininthetreatweat

of

gastria

caacenisbetteathaathatofaaatininaloae,antcombiaedtreatweat

caaredpcotheaCversereactioae

ofaaatinin

asweliasimprovatheqpdlityoflife.

Key

woait

:gastWocaaceainapaaad

stage;ShealinaBaizhpPowdea

aaatinin;atverse

re-

actioay

qpalityoflife

2

5

3%

~22%

[

o

,

2222-11

-15

(BK221510/6

RC221924

Y2219CX23

E-mail

***************

24

JournalofClinicalMedicineinPractice

24

1

1.1

2216

6

—2219

12

66

30

16

6

30-75

62

22

4

4

9

20

6

5

9

9

29~76

63

21

5

4

19

9

8

6

2

P

＞0.05

）,

AJCC

7

TNM

m

＞90d

RECIST

1

30d

1.0

500mg/d

1

/d

30d

1

2

1

22/

15/

20/

10//

15/

10/

3

22

/

15/

10/

5//

15/

1

/

1

/

15

10

10

15

15

15

2

0/

15/

15/

m15/

5

/

15/

5

/

15/

2

2

30d

1

2

1

1.3

RECIST[

CR

PR

SD

（PD

ORR

=（CR+PR

X150%

（DCR

=（CR+PR+

SD

X100%

WHO

（0~4

3

12

3

＞2/3

＞1/3

~2/3

1/3

=

+

X100%

1.0

SPSS19.0

t

P＜0.05

2

2.1

2

5

10

8

8

9

13

DCR

77.7%

3

50.0%

,

ORR

43.3%

26.0%

,

（P＜0.05）

2.0

2

2

1-

2

＞1

24

JournalofClinicalMedicineinPractice

25

(P

<

0.05

1

1

2

［”

)］

>1

1

2

3

4

15

5

2

0

7(23.3)

15

2

0

0

2(6.0)*

8

5

5

0

62000)

5

5

0

0

1303)*

3

6

2

0

8(26.7)

4

2

0

0

2(6.7)*

5

6

5

0

7(23.3)

3

5

0

0

1(30)*

4

4

5

0

51607)

3

5

0

0

1(3.3)

*P<0.05

40

2

4

15

11

63.3%

5

5

4

93.3%

(P<0.05)

3

4

VEGFR-2

MDR

li

1~2

CD4

FOLFOX4

0.05

［15］

Meta

NK

T

B

［1

］

FERLAY

jjSOERJOMATARAM

I,DIKSHITR

,

etal.Caee-

enieciCeeceana

mortality

worldwiCe:sources,methods

and

majorpatternoinGLOBOCAN2012

［J］.

lethCaecen,

2015

,

136(5)

:E322

-336.

［2

2015,

30(5

559-511.

［3

EDGESB

COMPTON

CC.

TheAmericae

JoieiCommii-

teeouCaecet

the7theeitiouoftheAJCCcancerstagingmac-

26

JooreclofCliniceiMedicineinPractice

24

uaianithefutureofTNM[J].AneSurgOecol,2015,17(

6):1471-1474.

[4]

[J.

2011,

30(11)

30-39.

[5]

.

2011

7.

2012,

4(5)

62­

71.

7]

M].

,2002

28-290.

[7]

EISENHAUER

EA,THERASSE

P,

BOGAERTS

J,etal.

Newresponse

evaluatioo

critericinsolidtumoug:revisedRE­

CIST/uineliou

(version1.1)

[J].

EueJCancer,

2009,

45

(2)

:228

[J]

MIYJ,LIANG

YJ,

HUANGHB,

etal.ApatiniC(YN968D1)

Reveees

MultiCruaResistance

byAhibihne

heEfUuxFuucOou

oUMultiptvATP-BinCine

CassetteTranspoUeru[J].CaneveRv-

parch,

2/19,

77(22)

:7901-7991.

[9]

LIJ,QIAS,XUJ,etal.ApatiniCforchemotUerany-refracto­

ryanvaeced

metntatie

gntrie

caecer:resultsfromaraneom-

ized,placedo-controlled

,parallel-rrm

,pPaseHtriat[J].

Cli-

0

01,2/13

,31(26)

3219

-3225.

[15]

LIJ,QIAS,XUJ

etal.Randomized

,douUle-Blinn,place-

bo-BOutrolledpPase

trialofapatinin

inpatients

w

PUceemo-

taerapyBefractora

anvaeced

ormetastaticanedocarcinoma

of

he

dumace

oegasUoesopha/eai

juncUou[J].

ClinOecoi,

2015,34(13)

1444-1454.

[H]

,

,

,

[J]

,

2013

,32(12)

:1444-1443.

[12]

71

[]•

,2019

,32(1):32-34.

[13]

,

,

[]•

,2013

,9(2)

33

-

39.

[14]

,

,

.

FOLFOX4

[]•

,

2019,

11(31)

84-8.

5

Meta

[J

,

209

9(4

557-463.

[9

•

2019

28

(3)

67-68

7

[]•

2009,

31(9)

973

-

975.

8

.

209,35(6

151-156.

[9]

BGCB23

[]•

2010,

25(3)

284-287.

[20

2017,

26(9

932-937.

(

22

2014,

14(2)

:77-79.

[2]

FIATKAUR,

LEWIAZKIV,KUHNTT,

eal.

AdPeauBpe-

cPicerterai

nututiou

FoeMulaimproves

nutetionai

statusanC

functiouai

peUormaace

inpatiedts

withheal

anCeeck.anCe-

sopha/eai

caacec

uuaeraoine

chemoranmtherapy

:results

oUa

ranComized,conUolled,

mulhceeter

thai[J].

Caacec,

2513,

95(9)

:3343

-3353.

•

2016

9

(6):959-961.

[4]

ANDON,KATOH,IGAKIH,etal.

AranComizedthalcom-

parine

postoperahve

adjuvact

chemotherapy

withcisplatin

anC

3-Buoropraci-

versus

preoperahve

ceemotUerany

Uelocalized

anvacced

squamous

cellcarcinoma

oUUe

thoracie

esophaeus

(JCOG9907)[J].

AncSuraOccoi,

2012,

9(1)

68-74.

2015

23(2

140-123.

[J]

2017,

23

(3)

/74-277.

•

2018,

53(12

lAYS-981.

2016(6

964

-196.

[9]

MCCLAVESA,TAYLOR

BE,

MARTIADALE

RG,etal.

Guinelices